Related references
Note: Only part of the references are listed.
Correction
Infectious Diseases
P. Arora et al.
LANCET INFECTIOUS DISEASES
(2023)
Article
Multidisciplinary Sciences
Yunlong Cao et al.
Summary: Continuous evolution of Omicron has led to the emergence of multiple variants with growth advantages, and mutations in their receptor-binding domain have converged on several hotspots, allowing them to evade neutralizing antibody drugs and convalescent plasma. Breakthrough infections of BA.2 and BA.5 have reduced the diversity of neutralizing antibody binding sites and promoted convergent evolution in the RBD.
Article
Biochemistry & Molecular Biology
Qian Wang et al.
Summary: The BQ and XBB subvariants of SARS-CoV-2 Omicron, with additional spike mutations, are rapidly expanding and have altered antibody evasion properties. Neutralization of BQ.1, BQ.1.1, XBB, and XBB.1 by vaccinated individuals and infected persons' sera was significantly impaired, including those boosted with a WA1/BA.5 bivalent mRNA vaccine. The titers against BQ and XBB subvariants were much lower than observed before, indicating that these subvariants pose a serious threat to current COVID-19 vaccines and render all authorized antibodies inactive.
Letter
Infectious Diseases
Prerna Arora et al.
LANCET INFECTIOUS DISEASES
(2023)
Article
Multidisciplinary Sciences
Ryuta Uraki et al.
Summary: The replicative ability and pathogenicity of Omicron BA.2 variant is similar to that of BA.1 in rodents, but it shows less pathogenicity compared to early SARS-CoV-2 strains. There is a marked reduction in the neutralizing activity of plasma from individuals who had recovered from COVID-19 and vaccine recipients against BA.2 variant.
Article
Multidisciplinary Sciences
Young-Jun Park et al.
Summary: SARS-CoV-2 Omicron sublineages have spike mutations that allow them to evade antibodies from previous infection or vaccination. Hybrid immunity or booster shots can generate neutralizing antibodies against Omicron variants, and breakthrough infections lead to the production of neutralizing antibodies in the nasal mucosa. Antibodies derived from memory B cells or plasma cells of Omicron breakthrough cases show cross-reactivity with different receptor-binding domains, while primary Omicron infections elicit B cells with narrow specificity. A highly potent pan-variant-neutralizing antibody has been identified as a potential candidate for clinical development.
Article
Multidisciplinary Sciences
Jean-Selim Driouich et al.
Summary: Despite limited pre-clinical evidence, repurposed drugs such as favipiravir are being extensively evaluated in clinical trials to combat the lack of antiviral options against SARS-CoV-2. Favipiravir shows strong antiviral efficacy in a Syrian hamster model, with high doses reducing viral infectivity while inducing mutations in viral genomes. However, toxicity concerns are noted at the highest tested dose, requiring further pharmacokinetic and tolerance studies before potential human use.
NATURE COMMUNICATIONS
(2021)
Article
Pharmacology & Pharmacy
Franck Touret et al.
Summary: The study evaluated the antiviral activity of imatinib and masitinib in pre-clinical models, showing activity in cells but failure to impair SARS-CoV-2 replication in in vivo models.
ANTIVIRAL RESEARCH
(2021)
